Eve Todesco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eve Todesco has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Anne-Geneviève Marcelin
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, laboratoire de virologie, F-75013 Paris, France
7 shared publicationsMarc-Antoine Valantin
Sorbonne University, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Pitié-Salpêtrière Hospital, Department of Infectious Diseases , F-75013 Paris
5 shared publications- Anne-Geneviève Marcelin
Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, 75013 Paris, France
4 shared publications - Thuy Nguyen
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
4 shared publications Vincent Calvez
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, laboratoire de virologie, F-75013 Paris, France
4 shared publicationsCorinne Amiel
Sorbonne Université, Centre d'Immunologie et de Maladies Infectieuses (CIMI) UMRS CR7, Persistent Viral Infection (PVI) Team, Inserm U1135, AP-HP, Groupe Hospitalier Paris Est, Hôpital Tenon, Laboratoire de virologie, F-75020 Paris, France
3 shared publications
Latest Publications
- 3 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , e449-e451
Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters
- 3 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (2) , e449-e451
Acute Hepatitis B among PWH Switched to Long-Acting Cabotegravir/Rilpivirine: The Context Matters
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des variants résistants minoritaires aux antirétroviraux : impact sur la réponse virologique au traitement
Les mutations de résistance pour une molécule sont produites avant que la molécule en question ne soit utilisée, et c’est sous « pression de sélection » que la souche résistante va être sélectionnée. Des données récentes montrent que des variants résistants minoritaires (VRMs) peuvent être une source d’échec virologique. Les nouvelles techniques de séquençage sont bien plus sensibles que les techniques classiques de séquençage et permettent la détection des VRMs. Afin d’évaluer l’intérêt de l’utilisation de ces techniques, nous avons étudié les prélèvements de patients en situation d’échec virologique après traitement par deux combinaisons antirétrovirales très utilisées (tenofovir/emtricitabine/efarirenz et tenofovir/emtricitabine/rilpivirine). De nombreux variants de résistance supplémentaires ont été détectés, touchant principalement la classe des Inhibiteurs Nucléosidiques de la Transcriptase Inverse (INTIs), avec un impact potentiel sur le choix du traitement de relais. Nous avons également étudié la prévalence des mutations de résistance transmise sur le gène de la protéase et de la transcriptase inverse chez des patients naïfs chroniquement infectés, chez deux groupes de transmission : des patients hommes ayant des rapports avec d’autres hommes (HSH), et des patients hétérosexuels. Nous avons retrouvé une prévalence plus élevée de mutations touchant les INTIs dans le groupe des patients hétérosexuels. Parmi les patients HSH, ceux infectés par un virus de sous-type B étaient plus fréquemment infectés par un virus résistant. Cette thèse met en avant la puissance des ces techniques, dont les conditions d'utilisation ne sont pas encore complètement définies.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des variants résistants minoritaires aux antirétroviraux : impact sur la réponse virologique au traitement
Les mutations de résistance pour une molécule sont produites avant que la molécule en question ne soit utilisée, et c’est sous « pression de sélection » que la souche résistante va être sélectionnée. Des données récentes montrent que des variants résistants minoritaires (VRMs) peuvent être une source d’échec virologique. Les nouvelles techniques de séquençage sont bien plus sensibles que les techniques classiques de séquençage et permettent la détection des VRMs. Afin d’évaluer l’intérêt de l’utilisation de ces techniques, nous avons étudié les prélèvements de patients en situation d’échec virologique après traitement par deux combinaisons antirétrovirales très utilisées (tenofovir/emtricitabine/efarirenz et tenofovir/emtricitabine/rilpivirine). De nombreux variants de résistance supplémentaires ont été détectés, touchant principalement la classe des Inhibiteurs Nucléosidiques de la Transcriptase Inverse (INTIs), avec un impact potentiel sur le choix du traitement de relais. Nous avons également étudié la prévalence des mutations de résistance transmise sur le gène de la protéase et de la transcriptase inverse chez des patients naïfs chroniquement infectés, chez deux groupes de transmission : des patients hommes ayant des rapports avec d’autres hommes (HSH), et des patients hétérosexuels. Nous avons retrouvé une prévalence plus élevée de mutations touchant les INTIs dans le groupe des patients hétérosexuels. Parmi les patients HSH, ceux infectés par un virus de sous-type B étaient plus fréquemment infectés par un virus résistant. Cette thèse met en avant la puissance des ces techniques, dont les conditions d'utilisation ne sont pas encore complètement définies.
- Open Access
- 29 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108359
The DePASS initiative in healthcare access units: Do not miss the opportunity to detect HIV, HBV, and HCV
- 29 December 2025
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 164, 108359
Open AccessThe DePASS initiative in healthcare access units: Do not miss the opportunity to detect HIV, HBV, and HCV
- Open Access
- 25 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2452
Author Correction: T cell malignancies after CAR T cell therapy in the DESCAR-T registry
- 25 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2452
Open AccessAuthor Correction: T cell malignancies after CAR T cell therapy in the DESCAR-T registry
- Top Cited Papers
- 8 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (4) , 1130-1133
T cell malignancies after CAR T cell therapy in the DESCAR-T registry
The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018. Of the 3,066 patients included (2,536 B cell lymphoma, 162 B cell acute lymphoblastic leukemia (ALL) and 368 multiple myeloma), 1,680 (54.8%) received axicabtagene ciloleucel, 205 (6.7%) brexucabtagene autoleucel, 44 (1.4%) lisocabtagene maraleucel and 769 (25.1%) tisagenlecleucel. All multiple myeloma patients received idecabtagene vicleucel, with none receiving ciltacabtagene autoleucel. After a median follow-up of 12.7 months for B cell lymphoma, 17.7 months for B cell ALL and 6.3 months for multiple myeloma, only one (0.03%) patient developed a T cell malignancy after CAR T infusion. Specifically, the patient was diagnosed with a primary cutaneous CD30+ T cell lymphoproliferative disorder (anaplastic lymphoma kinase-negative) 3 years after receiving tisagenlecleucel therapy for diffuse large B cell lymphoma. This was associated with the integration of a CAR clone into the tumor suppressor gene PLAAT4 (phospholipase A and acyltransferase 4). Thus, the development of this secondary T cell malignancy might be linked to the use of CAR T cell therapy. In conclusion, our findings indicate a very low risk of T cell malignancy after CAR T cell therapy.
- 8 January 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (4) , 1130-1133
Top Cited PapersT cell malignancies after CAR T cell therapy in the DESCAR-T registry
The risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018. Of the 3,066 patients included (2,536 B cell lymphoma, 162 B cell acute lymphoblastic leukemia (ALL) and 368 multiple myeloma), 1,680 (54.8%) received axicabtagene ciloleucel, 205 (6.7%) brexucabtagene autoleucel, 44 (1.4%) lisocabtagene maraleucel and 769 (25.1%) tisagenlecleucel. All multiple myeloma patients received idecabtagene vicleucel, with none receiving ciltacabtagene autoleucel. After a median follow-up of 12.7 months for B cell lymphoma, 17.7 months for B cell ALL and 6.3 months for multiple myeloma, only one (0.03%) patient developed a T cell malignancy after CAR T infusion. Specifically, the patient was diagnosed with a primary cutaneous CD30+ T cell lymphoproliferative disorder (anaplastic lymphoma kinase-negative) 3 years after receiving tisagenlecleucel therapy for diffuse large B cell lymphoma. This was associated with the integration of a CAR clone into the tumor suppressor gene PLAAT4 (phospholipase A and acyltransferase 4). Thus, the development of this secondary T cell malignancy might be linked to the use of CAR T cell therapy. In conclusion, our findings indicate a very low risk of T cell malignancy after CAR T cell therapy.
- 4 May 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (1) , 88-90
High rate of early HEV seroconversion after liver transplantation among cirrhotic patients: Should we test for it?
- 4 May 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (1) , 88-90
High rate of early HEV seroconversion after liver transplantation among cirrhotic patients: Should we test for it?
- 13 April 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (1) , 62-63
SARS-CoV-2 variant-dependent inflammasome activation
- 13 April 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (1) , 62-63
SARS-CoV-2 variant-dependent inflammasome activation
- Open Access
- 22 December 2022
- Published by MDPI AG in Microorganisms
- Vol. 11 (1) , 30
Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations
SARS-CoV-2 expresses on its surface the Spike protein responsible for binding with the ACE2 receptor and which carries the majority of immunodominant epitopes. Mutations mainly affect this protein and can modify characteristics of the virus, giving each variant a unique profile concerning its transmissibility, virulence, and immune escape. The first lineage selected is the B.1 lineage characterized by the D614G substitution and from which all SARS-CoV-2 variants of concern have emerged. The first three variants of concern Alpha, Beta, and Gamma spread in early 2021: all shared the N501Y substitution. These variants were replaced by the Delta variant in summer 2021, carrying unique mutations like the L452R substitution and associated with higher virulence. It was in turn quickly replaced by the Omicron variant at the end of 2021, which has predominated since then, characterized by its large number of mutations. The successive appearance of variants of concern showed a dynamic evolution of SARS-CoV-2 through the selection and accumulation of mutations. This has not only allowed progressive improvement of the transmissibility of SARS-CoV-2, but has also participated in a better immune escape of the virus. This review brings together acquired knowledge about SARS-CoV-2 variants of concern and the impacts of the Spike mutations.
- 22 December 2022
- Published by MDPI AG in Microorganisms
- Vol. 11 (1) , 30
Open AccessEpidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations
SARS-CoV-2 expresses on its surface the Spike protein responsible for binding with the ACE2 receptor and which carries the majority of immunodominant epitopes. Mutations mainly affect this protein and can modify characteristics of the virus, giving each variant a unique profile concerning its transmissibility, virulence, and immune escape. The first lineage selected is the B.1 lineage characterized by the D614G substitution and from which all SARS-CoV-2 variants of concern have emerged. The first three variants of concern Alpha, Beta, and Gamma spread in early 2021: all shared the N501Y substitution. These variants were replaced by the Delta variant in summer 2021, carrying unique mutations like the L452R substitution and associated with higher virulence. It was in turn quickly replaced by the Omicron variant at the end of 2021, which has predominated since then, characterized by its large number of mutations. The successive appearance of variants of concern showed a dynamic evolution of SARS-CoV-2 through the selection and accumulation of mutations. This has not only allowed progressive improvement of the transmissibility of SARS-CoV-2, but has also participated in a better immune escape of the virus. This review brings together acquired knowledge about SARS-CoV-2 variants of concern and the impacts of the Spike mutations.
- 16 February 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 28 (6) , 900-902
High SARS-CoV-2 seroprevalence among health care workers in Bamako referral hospitals: a prospective multisite cross-sectional study (ANRS COV11)
- 16 February 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 28 (6) , 900-902
High SARS-CoV-2 seroprevalence among health care workers in Bamako referral hospitals: a prospective multisite cross-sectional study (ANRS COV11)
- Open Access
- 24 June 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (6) , 1093-1096
Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.
- 24 June 2021
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (6) , 1093-1096
Open AccessPoor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients
A low anti-spike antibody response of 28.6% was observed 28 days after BNT162b2 vaccine second dose among 133 solid organ transplant recipients without previous coronavirus disease 2019 (COVID-19). No serious adverse events were recorded. Four severe COVID-19 cases were reported between or after the 2 doses. Our data suggest to change the vaccine strategy.